Adult Immunization

 
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates
April 02, 2025

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

Sanofi's Chlamydia Vaccine Granted FDA Fast Track Designation
March 26, 2025

The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.

Improved HPV Vaccination Coverage May Help Prevent Noncervical Cancers in People with HIV
March 19, 2025

CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.

US Adult Vaccination Snapshots: Current Coverage, Trends, and Concerns
March 19, 2025

Get the latest immunization updates, data on racial disparities, and practical guidance for clinical practice, here.

FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
February 27, 2025

Your daily dose of the clinical news you may have missed.

FDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care Use
February 24, 2025

The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.

FDA Approves GSK's Pentavalent Meningococcal Vaccine Penmenvy
February 17, 2025

The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.

17 Adult Vaccines: Who to Consider for Each
February 11, 2025

A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: Health, Age, Lifestyle, and Occupation, or HALO.

Vaccine Hesitancy in the Chronic Conditions Community: New Survey Findings
January 24, 2025

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

Sen-Jam Pharmaceutical Reports Preliminary Phase 2 Results for SJP-002C in COVID-19 Treatment
January 20, 2025

The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.